FRESENIUS SE+CO.KGAA O.N./ DE0005785604 /
11/8/2024 12:53:55 PM | Chg. +0.030 | Volume | Bid8:36:49 PM | Ask8:36:49 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
33.850EUR | +0.09% | 517 Turnover: 17,563.720 |
-Bid Size: - | -Ask Size: - | 19.21 bill.EUR | - | - |
GlobeNewswire
4/23
Transferring Biomedical Research to Patients Faster: ForTra gGmbH Announces Positive Funding Track R...
GlobeNewswire
2/23
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatm...
GlobeNewswire
9/4/2023
CIO Leadership: Generative AI and Visionary Leadership in the Enterprise Will Power the Discussion a...
GlobeNewswire
8/31/2023
CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil
GlobeNewswire
8/24/2023
CIO Leadership: The Steps Needed to Build a High-Performance Culture Will Power the Discussion at th...
GlobeNewswire
2/25/2022
Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodia...
GlobeNewswire
1/5/2022
Oculis appoints Mr. Webb Ding as Global Chief Operating Officer and General Manager (China)
GlobeNewswire
12/31/2021
CIO Leadership: HMG Strategy, the World’s #1 Executive Leadership Network, Looks Ahead to its 15th Y...
GlobeNewswire
12/9/2021
Angion and Vifor Pharma Report Topline Results from Phase 2 GUARD Trial of ANG-3777 in Cardiac Surge...
GlobeNewswire
11/22/2021
Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology
GlobeNewswire
11/22/2021
Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology